KRTAP16-8 Inhibitors
KRTAP16-8 inhibitors are part of a chemical class composed of compounds specifically designed to target and disrupt the activity of KRTAP16-8, a protein belonging to the Keratin-Associated Protein (KRTAP) family. These proteins are predominantly expressed in hair and hair follicles, where they play pivotal roles in shaping the structural and mechanical properties of hair fibers. KRTAP16-8, as a member of this family, is presumed to contribute to the structural integrity and functional characteristics of hair.
KRTAP16-8 inhibitors exert their primary mechanism of action by interacting with the KRTAP16-8 protein or its associated molecules, leading to the modulation of its normal function. By inhibiting KRTAP16-8, these compounds have the ability to influence processes related to hair development, hair structure, or other cellular functions in which this protein is involved. However, the precise functions and molecular pathways associated with KRTAP16-8 are still subjects of active investigation. Scientists researching KRTAP16-8 inhibitors aim to uncover the exact roles and significance of KRTAP16-8 within the context of hair biology and other relevant cellular processes. These inhibitors serve as essential tools for advancing our understanding of KRTAP16-8 and its roles in cellular functions. In this context, they contribute to expanding our knowledge of the intricate interactions and functions of keratin-associated proteins in the biology of hair and related tissues.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine can incorporate into RNA and DNA, demethylating DNA and potentially altering gene expression, including that of KRTAP6-5. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
Decitabine is a DNA methyltransferase inhibitor that could lead to DNA hypomethylation and subsequent changes in gene expression profiles. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Vorinostat, a histone deacetylase inhibitor, may increase histone acetylation and alter the expression of a wide array of genes. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
5-Fluorouracil is metabolized to nucleotide analogs that can be incorporated into RNA and DNA, disrupting normal gene expression and protein synthesis. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide has been shown to inhibit transcriptional activity by affecting RNA polymerase II, potentially decreasing gene expression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits the 26S proteasome, leading to altered protein degradation and potentially impacting gene expression indirectly. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, which can affect protein folding and stability, indirectly influencing gene expression. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $163.00 $316.00 | 436 | |
Puromycin causes premature chain termination during translation and may indirectly affect the stability of mRNA, impacting protein synthesis. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid acts as a ligand for retinoic acid receptors, potentially modulating gene transcription across a range of gene families. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide binds to the E3 ubiquitin ligase complex, affecting the degradation of various transcription factors, which may alter gene expression patterns. | ||||||